Moolec Science (MLECW) Gross Profit (2023 - 2024)
Moolec Science (MLECW) posted Gross Profit of -$674369.0 for Q4 2024, down 4664.88% sequentially from $14773.0 in Q3 2024, and down 390.58% YoY from $232074.0 in Q1 2024.
Moolec Science (MLECW) Gross Profit (2023 - 2024) Analysis & Trends
Moolec Science has reported Gross Profit for 2 years, with the latest figure at -$674369.0 in Q4 2024.
- Quarterly Gross Profit fell 390.58% year-over-year to -$674369.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$639496.0 (changed N/A YoY) and the FY2024 annual result came in at $186.6 million, up 1.08% from the prior year.
- Gross Profit eased to -$674369.0 in Q4 2024 per MLECW's latest filing, from $14773.0 in the prior quarter.
- Over five years, Gross Profit peaked at $232074.0 in Q4 2023 and troughed at -$674369.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -674,369.00 |
| Dec 31, 2024 | -674,369.00 |
| Sep 30, 2024 | 14,773.00 |
| Sep 30, 2024 | 14,773.00 |
| Jun 30, 2024 | -71,643.00 |
| Jun 30, 2024 | -71,643.00 |
| Mar 31, 2024 | 91,743.00 |
| Mar 31, 2024 | 91,743.00 |
| Dec 31, 2023 | 232,074.00 |
| Dec 31, 2023 | 232,074.00 |
| Sep 30, 2023 | 220,408.00 |
| Sep 30, 2023 | 220,408.00 |